Sareum (LON:SAR) Announces Earnings Results

Sareum (LON:SAR) posted its quarterly earnings results on Tuesday. The company reported GBX (0.90) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Sareum Stock Up 4.3 %

SAR stock opened at GBX 12.52 ($0.16) on Thursday. The business’s 50-day simple moving average is GBX 17.82 and its 200 day simple moving average is GBX 23.19. The company has a market cap of £15.64 million, a PE ratio of -2.96 and a beta of -1.08. Sareum has a twelve month low of GBX 10 ($0.13) and a twelve month high of GBX 52.50 ($0.68).

Insider Buying and Selling at Sareum

In other news, insider Stephen Parker acquired 84,033 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of GBX 12 ($0.15) per share, for a total transaction of £10,083.96 ($12,983.08). Insiders own 5.02% of the company’s stock.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.